Aripiprazole (OPC-14597), an atypical antipsychotic, is a potent and high-affinity dopamine D2 receptor partial agonist. Aripiprazole is an inverse agonist at 5-HT2B and 5-HT2A receptors and displays partial agonist actions at 5-HT1A, 5-HT2C, D3, and D4 receptors. Aripiprazole can be used for the research of schizophrenia and COVID19.
性状
Solid
IC50 & Target[1][2]
5-HT1A Receptor 4.2 nM (Ki) 5-HT2A Receptor
体外研究(In Vitro)
Aripiprazole potently activates D2 receptor-mediated inhibition of cAMP accumulation.Aripiprazole shows a greater anti-inflammatory effect on TNF-α, IL-13, IL-17α and fractalkine. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
Aripiprazole (0-3 mg/kg, IP, daily) shows some anxiolytic properties. has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: WAG/Rij rats (N = 6 per dose, 6 months, administration of a mixtu
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
4°C, protect from light In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
ClinicalTrial
参考文献
[1]. Burris KD, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002 Jul;302(1):381-9.[2]. Davies MA, et al. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev. 2004 Winter;10(4):317-36.
溶解度数据
In Vitro: DMSO : 100 mg/mL (223.02 mM; Need ultrasonic)DMF : 50 mg/mL (111.51 mM; Need ultrasonic)配制储备液